Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

NINJ1 is activated by Mycobacterium tuberculosis ESX-1 secreted effector EsxA and mediates necrosis of infected human macrophages

Created on 05 Nov 2025

Authors

Saetra, R. S. R., Hansen, M., Kappelhoff, S., Bugge, M., Marstad, A., Ryan, L., Devant, P., Kagan, J. C., Freude, K. K., Beckwith, K. S., FLO, T. H.

Abstract

Lytic cell death is recognized as a driver of tissue damage and dissemination during Mycobacterium tuberculosis (Mtb) infection, yet its execution mechanisms remain incompletely defined. Here, we identify Ninjurin-1 (NINJ1), a mediator of plasma membrane rupture (PMR), as a central effector of macrophage lysis in response to Mtb. Infection triggered NINJ1 oligomerization, and genetic or pharmacological inhibition of NINJ1 markedly reduced lactate dehydrogenase (LDH) release. Surprisingly, individual or combined inhibition of pyroptosis, apoptosis, necroptosis, or ferroptosis failed to prevent PMR in Mtb-infected macrophages. Instead, the ESX-1-secreted effector EsxA directly induced NINJ1 oligomerization, implicating pathogen-driven membrane damage as the upstream trigger. NINJ1 activation was independent of calcium or high-MW PEG, although PEG reduced LDH-release, implicating swelling-induced membrane changes in PMR. Cytokine release was mostly NINJ1-independent, except for CXCL-10, which was diminished in NINJ1-deficient macrophages. These findings establish NINJ1 as a key executioner of lytic cell death during Mtb-infection.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 05 Nov 2025.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 49
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement